Tag : ASCVD

CONFERENCE UPDATE

The Ez-PAVE trial: Intensive LDL-C targeting reduces 3-year CV events in ASCVD patients
The Ez-PAVE trial showed that intensive LDL-C targeting <55mg/dL significantly reduced 3-year composite cardiovascular events compared with conventional targeting <70mg/dL in patients with ASCVD, without increasing major safety concerns, supporting a more aggressive LDL-C control in line with current guidelines.
CONFERENCE UPDATE

Inclisiran-based strategy improves LDL-C goal attainment and safety: Results from the phase 4 VICTORION-Difference trial
STUDY DESIGN Atherosclerotic cardiovascular disease remains a substantial health burden, with low-density lipoprotein cholesterol established as a causal risk factor in both its development and progression.
CONFERENCE UPDATE

Triglyceride reduction with olezarsen in HTG patients with high CV risk: The BRIDGE-TIMI 73a trial
CONFERENCE UPDATE

“Inclisiran first” strategy lowers LDL-C in real-world ASCVD patients: Results from the VICTORION-INITIATE trial
A reduction in LDL-C is associated with improvements in CV outcomes in patients with ASCVD.1 As such, multiple guidelines recommend LDL-C targets of <55mg/dL and <70mg/dL based on baseline risks. However, many patients fail their LDL-C goals due to clinical inertia, medication nonadherence, side effects, and/or poor healthcare access. Inclisiran is a first-in-class siRNA that inhibits hepatic PCSK9 production and increases LDL receptor expression and LDL-C clearance. In clinical studies, twice-yearly administration of inclisiran has been shown to achieve a 50% reduction in LDL-C.